Evercore ISI Group Downgrades AN2 Therapeutics to In-Line, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko downgraded AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and reduced the price target from $25 to $7.
February 12, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AN2 Therapeutics was downgraded by Evercore ISI Group from Outperform to In-Line, with a significant reduction in price target from $25 to $7.
The downgrade from Outperform to In-Line and the substantial reduction in price target from $25 to $7 by a reputable analyst group like Evercore ISI Group is likely to negatively impact investor sentiment towards AN2 Therapeutics in the short term. This could lead to a decrease in stock price as investors adjust their expectations based on the new analyst rating and price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100